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Abstract
Synaptic pathology is associated with several brain disorders, thus positron emission tomography (PET) imaging of
synaptic vesicle glycoprotein 2A (SV2A) using the radioligand [11C]UCB-J may provide a tool to measure synaptic
alterations. Given the pivotal role of mouse models in understanding neuropsychiatric and neurodegenerative disorders,
this study aims to validate and characterize [11C]UCB-J in mice. We performed a blocking study to verify the specificity of
the radiotracer to SV2A, examined kinetic models using an image-derived input function (IDIF) for quantification of the
radiotracer, and investigated the in vivo metabolism. Regional TACs during baseline showed rapid uptake of [11C]UCB-J
into the brain. Pretreatment with levetiracetam confirmed target engagement in a dose-dependent manner. VT (IDIF)
values estimated with one- and two-tissue compartmental models (1TCM and 2TCM) were highly comparable (r¼0.999,
p< 0.0001), with 1TCM performing better than 2TCM for K1 (IDIF). A scan duration of 60min was sufficient for reliable
VT (IDIF) and K1 (IDIF) estimations. In vivo metabolism of [
11C]UCB-J was relatively rapid, with a parent fraction of
22.5 4.2% at 15min p.i. In conclusion, our findings show that [11C]UCB-J selectively binds to SV2A with optimal
kinetics in the mouse representing a promising tool to noninvasively quantify synaptic density in comparative or thera-
peutic studies in neuropsychiatric and neurodegenerative disorder models.
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Introduction
Synaptic vesicles play an essential role in neurotrans-
mitter release from the presynaptic terminals following
action potential stimulation.1 The synaptic vesicle
glycoprotein 2 (SV2) is a highly conserved protein
family in all vertebrates that displays a vital role in
physiological synaptic functionality.2 SV2 proteins are
divided into three isoforms, which show differential
expression. SV2A is the predominant isoform, SV2B
is also widely-expressed, although not as extensively
as SV2A, and SV2C is only present in specific brain
regions.3–5 Indeed, SV2A is expressed ubiquitously in
virtually all synapses3 and its role has been shown to be
vital as mice lacking SV2A develop spontaneous
seizures and die postnatally due to destabilization of
synaptic circuits.4,6 In addition, SV2A is the binding
site of the antiepileptic drug levetiracetam (LEV)7 and
dysfunction of SV2A has also been associated with the
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pathophysiology of epilepsy8 as well as other neuro-
logical disorders.9
Since SV2A is homogenously distributed in synaptic
vesicles,10 quantifying SV2A offers the opportunity to
monitor changes in synaptic density. Different radio-
tracers to visualize SV2A in vivo using positron emis-
sion tomography (PET) have been described, including
[11C]UCB-J, [18F]UCB-H, and [11C]UCB-A.11–14
[11C]UCB-J appears the most promising due to its
optimal pharmacokinetics and quantification proper-
ties as recently reported in both non-human primates11
and healthy humans.15,16 In addition, recent studies
have demonstrated the feasibility of [11C]UCB-J PET
in detecting pathological changes in synaptic density in
patients with mesial temporal lobe epilepsy,16
Alzheimer’s disease,17 and depression.18
However, although in vivo PET imaging using
[11C]UCB-J has been published in humans and
non-human primates, to date no study validating the
binding nor characterizing the kinetics of [11C]UCB-J
PET imaging in rodents has been described. Mouse
models play a crucial role in biomedical research19
for the translation of basic research findings into the
clinical applications. Given the invaluable importance
of mouse models in studying neuropsychiatric and neu-
rodegenerative disorders, and the broad spectrum of
diseases characterized by synaptic dysfunction, applica-
tion of [11C]UCB-J PET imaging in mice would provide
significant advances in understanding the pathophysi-
ology and diagnosis of neurological disorders.20 The
aim of the present study was to validate the specific
binding and to provide the methodology for noninva-
sive in vivo quantification of [11C]UCB-J PET imaging
in mice in order to apply this radiotracer in preclinical
studies. We performed a blocking study to verify the
specificity of the radiotracer to SV2A, examined kinetic
models and parameter estimations for quantification of
the radiotracer, and investigated the in vivo metabolism
of [11C]UCB-J in plasma of healthy and Huntington’s
Disease model (HD) mice.
Materials and methods
Animals
A total of 38 male mice (C57BL/6J) were obtained from
Jackson Laboratories (Bar Harbour, Maine, USA)
and included in the study. In vivo PET imaging was
performed in eight-months-old male wild-type
(C57BL/6J, WT, n¼ 10). For the generation of a popu-
lation-based metabolite curve, six-months-old WT and
heterozygous littermates (Q175DN mouse model of
Huntington’s disease, HD) were included (n¼ 15 per
genotype). Animals were group-housed in individually
ventilated cages under a 12-h light/dark cycle in a
temperature- and humidity-controlled environment
with food and water ad libitum. At least one week of
acclimatization was allowed before the start of the pro-
cedures. All experiments were performed according to
the European Committee Guidelines (decree 2010/63/
CEE) and the Animal Welfare Act (7 USC 2131), and
reported in compliance with the ARRIVE guidelines.
Experiments were approved by the Ethical Committee
for Animal Testing (ECD 2017-27) at the University of
Antwerp (Belgium).
Radiotracer synthesis
[11C]UCB-J synthesis was performed on an automated
synthesis module (Carbosynthon I, Comecer, The
Netherlands) adapting the previously described proced-
ure11 to our system. Briefly, [11C]UCB-J compound was
synthetized via a single-step carbon-11 labelling start-
ing with a mixture of trifluoroborate and boric acid
precursors (ratio 95:5), which was prepared prior to
the synthesis and reacted with [11C]MeI already trapped
into DMF. Reaction occurred in the presence of palla-
dium catalyst (Pd2(dba)3), P(o-tol)3, and a base
(K2CO3) in DMF for 5min at 100
C. Trapping of
[11C]MeI in the reactor with DMF prior to the addition
of the mixture was required for the reaction. Average
radiochemical purity was greater than 99%, and the
molar activity was 78.8 23.0GBq/mmol.
PET acquisition and reconstruction
Ninety-minute dynamic microPET/computed tomog-
raphy (CT) images were acquired on two Siemens
Inveon PET-CT scanners (Siemens Preclinical
Solution, Knoxville, USA). Anaesthesia was induced
and maintained using isoflurane (Forene, Belgium;
5% and 1.5%, respectively) in oxygen. Animals
(n¼ 10) were catheterized in the tail vein for intraven-
ous (i.v.) administration of the tracer and positioned
onto the scanner. Physiological parameters (respiration
and temperature) were continuously monitored and
kept constant throughout the procedure using a
Monitoring Acquisition Module (Minerve, France).
At the onset of the dynamic PET scan, bolus injection
was performed using an automated pump (Pump 11
Elite, Harvard Apparatus, USA) over a 12 s interval
(1ml/min). Following the microPET scan, a 10min
80 kV/500 lA CT scan was performed for attenuation
correction as well as for anatomical registration.
A blocking study to validate specificity of [11C]UCB-
J binding was performed using the antiepileptic drug
LEV (Merck, Germany), a high affinity ligand for
SV2A,21 at two different doses that displayed antiepi-
leptic effects in mouse models of epilepsy22,23 (50 and
200mg/kg i.p.; n¼ 4 per dose) in the same animals
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scanned at baseline. LEV was dissolved in saline and
injected 30min before administration of [11C]UCB-J.
Methodologically, no significant difference between
baseline and blocking PET scans was observed in the
injected activity (baseline¼ 4.5 1.2MBq, LEV50¼
3.6 0.7MBq, LEV200¼ 4.3 0.3MBq; p¼ 0.251),
body weight (baseline¼ 31.2 0.9 g, LEV50¼
30.7 0.1 g, LEV200¼ 31.4 1.5 g; p¼ 0.606), or
injected mass (baseline¼ 1.0 0.3mg/kg, LEV50¼
1.2 0.4 mg/kg, LEV200¼ 1.02 0.3 mg/kg; p¼ 0.226).
Acquired PET data were histogrammed and recon-
structed into 39 frames of increasing length (12 10 s,
3 20 s, 3 30 s, 3 60 s, 3 150 s and 15 300 s). For
quantitative analysis, all images were reconstructed
using a list-mode iterative reconstruction with propri-
etary spatially variant resolution modeling in 8 iter-
ations and 16 subsets of the 3D ordered subset
expectation maximization (OSEM 3D) algorithm.
Normalization, dead time, and CT-based attenuation
corrections were applied. PET image frames were
reconstructed on a 128 128 159 grid with
0.776 0.776 0.776mm3 voxels.
Image processing and kinetic modeling
Analysis and processing of the PET data were per-
formed using PMOD 3.6 software (Pmod
Technologies, Zurich, Switzerland). In order to achieve
spatial normalization of the PET images, a [11C]UCB-J
PET template was generated using the 90-min static
PET images of the baseline scans, adapting the proced-
ure we previously described24 to [11C]UCB-J.
Individual static [11C]UCB-J PET images were spatially
normalized to this [11C]UCB-J PET template through
non rigid brain normalization. The spatial transform-
ations were saved and applied to dynamic PET imaging
frames. For the blocking experiment, the PET template
approach could not be applied due to lack of specific
signal. Therefore, for these data, individual CT images
were spatially normalized to the CT image of the
[11C]UCB-J PET template adapting the procedure we
previously described.24 All images were visually
checked for accuracy following spatial transformation.
Since the [11C]UCB-J PET template was generated in
the same space of the Waxholm atlas,25 volumes-of-
interest (VOIs) were adapted from that atlas.
Regional time-activity curves (TACs) were calculated
for the following regions: striatum (STR), thalamus
(THAL), motor cortex (MC), hippocampus (HC), and
cerebellum (CB).
Kinetic analysis was performed by fitting the regio-
nal TACs with the one-tissue compartmental model
(1TCM), two-tissue compartmental model (2TCM)
and Logan plot method.26 We estimated the total
blood radioactivity using a noninvasive image-derived
input function (IDIF) to obtain VT (IDIF) as a surrogate
of VT. For the compartmental models, the blood
volume fraction (VB) was fixed at 3.6%,
27 while for
the Logan plot the linear phase (t*) was determined
from the curve fitting with t* ranging from 7.5 to
12.5min. The aforementioned IDIF was extracted
from the PET images measuring the whole blood activ-
ity in the lumen of the left ventricle of the heart. Such
was achieved by generating a volume-of-interest on the
early time frame exhibiting maximal activity in the
heart with a threshold considering 50% of the max
intensity as previously described.28 This approach
allows to perform comparative studies in mice avoiding
extensive blood (or plasma) sampling which is not
achievable in longitudinal studies.
When performing full kinetic modeling, it is
possible to estimate the microparameters K1 and k2
29
in addition to the macroparameter VT, which is the
theoretical volume of tissue needed to contain the
total amount of radiotracer at the concentration in
metabolite-corrected plasma at equilibrium. K1 repre-
sents the delivery rate of the tracer and is hence an
indication of the cerebral blood flow, while k2 depicts
the transport of the tracer from the tissue back to the
blood. K1 is dependent on perfusion, while k2 is
coupled to K1.
During the blocking study, only the Logan plot
method was used for kinetic modeling since assessment
of the microparameters was not required. In addition,
an estimation of the regional non-displaceable binding
potential (BPND) was calculated as ratio of VT and
VND minus 1 (DVR-1)
30 using the individual regional
VT (IDIF) values of baseline scans for VT and the group
regional VT (IDIF) values during the blocking with high-
est dose (200mg/kg) as an estimate for the non-
displaceable volume of distribution (VND)
(Supplemental Table 1).
Parametric images were generated with PMOD 3.6
software using the pixel-wise modeling tool (PXMOD)
through voxel-based graphical analysis (Logan plot,
VT (IDIF) images) and 1TCM
31 (VT (IDIF) and K1 (IDIF)
images) with the IDIF as input function, represented as
group averages, and overlaid onto a 3D coronal/
sagittal/transversal mouse brain template for anatom-
ical reference.
To determine the relative performance of each model
to fit the regional PET data, the goodness-to-fit was
calculated using the Akaike Information Criterion
(AIC),32 the Model Selection Criterion (MSC), a mod-
ified version of the AIC criterion used in the Scientist
Software (MicroMath, Saint Louis, Missouri USA),
and the F-test.33
To estimate the extent of target occupancy reached
during the PET scan with LEV pretreatment, we
employed the Lassen plot,34 which also provides an
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estimate of the VND,
35 based on the regional changes in
VT (IDIF) following drug administration.
To evaluate the time stability of the VT (IDIF) and K1
(IDIF) values, PET data were analysed by repeatedly
excluding the last 5min of PET acquisition from
90min down to 20min. The 90min PET acquisition
was considered the reference outcome to which values
obtained from shorter acquisition were compared to.
Quantification of PET data was considered acceptable
when the average percentage difference compared to the
90min PET acquisition was less than 10% with an
inter-individual standard deviation lower than 5%.
Metabolite analysis and correction
In vivo plasma metabolite analysis was performed at 5,
15, 30, and 45min post-injection (p.i.). The procedure
was done in six-months-old wild-type (WT) mice as
well as Q175DN heterozygouos mice (n¼ 3 per time
point/genotype) with the aim to characterize the metab-
olism of [11C]UCB-J in mice and to investigate possible
disease-associated differences in radiotracer metabolism
as well as for generation of a population-based curve to
correct for this radiometabolism in the quantification.
Mice were injected via the lateral tail vein with
[11C]UCB-J (4.9 1.6MBq in 200ll) and blood was
withdrawn via cardiac puncture at 5, 15, 30, and
45min p.i. Our procedure was previously described36
and currently adapted as follows: plasma samples
(200ll), obtained after centrifugation of blood at
4500 r/min (2377 rcf) for 5 min, were mixed with
equal amounts of ice-cold acetonitrile. Then, 10ml of
cold reference were added (1mg/ml), and subsequently
centrifuged at 4500 rpm (2377 rcf) for 5min to pre-
cipitate denatured proteins. Supernatant was separated
from the precipitate and both fractions were counted in
a gamma counter to calculate the extraction efficiency
(percentage of recovery of radioactivity), which was
97.3 4.8%. Next, 100ll of supernatant were loaded
onto a pre-conditioned reverse-phase (RP)-HPLC
system (Kinetex, 150 4.6mm, 5lm HPLC columnþ
Phenomenex security guard pre-column) and eluted
with NaOAc 0.05M pH5.5 and acetonitrile (68:32v/v)
buffer at a flow rate of 1.5ml/min. RP-HPLC fractions
were collected at 0.5min intervals for 8min and radio-
activity was measured in a gamma counter. The radio-
activity was expressed as a percentage of the total area of
the peaks based on the radiochromatograms.
To determine the recovery of [11C]UCB-J as well as
the stability of the tracer during the workup, control
experiments were performed using blood spiked in vitro
with 37 kBq of radiotracer. Sample workup was identi-
cal as described and confirmed that no degradation of
the tracers occurred during procedural work-up
(99.7 0.25% of intact tracer).
To generate the population-based curve to account
for peripheral radiometabolism, we used the parent frac-
tions measured in WT mice at different times p.i.
In PMOD 3.6 software, values were fitted using a sig-
moid curve as this model provided the best fit compared
to other models (i.e. Watabe, Hill, 1-Exponential,
2-Exponentials, and 3-Exponentials). Thus, each individ-
ual IDIF was corrected for the sigmoid curve of the
parent fraction and the plasma-to-whole blood ratio,
calculated based on the radiometabolite analysis data,
in order to derive the metabolite-corrected input func-
tion to use for kinetic modeling.
Statistical analysis
Two-way ANOVA was applied to the blocking experi-
ment to compare baseline and blockade scans in the
different regions. Pearson’s correlation tests as well as
Bland-Altman plots were used to compare VT (IDIF) and
K1 (IDIF) values determined with different kinetic
models. In addition, Pearson’s correlation tests were
used to compare the effect of shortening the PET acqui-
sition, to correlate the VT (IDIF) values either corrected
or not for metabolism, and for the Lassen plots. The
percentage of the intra-animal coefficient of variation
(COV) within each kinetic model and brain region was
calculated as follows
COV ¼ 1
N
XN
i
SDi
xi
where N represents the number of measurements in the
group, xi and SDi respectively the mean and standard
deviation of the values for measurement i. All analyses
were performed with GraphPad Prism (v 6.0) statistical
software. The data are represented as mean standard
deviation (SD). All tests were two-tailed and signifi-
cance was set at p< 0.05.
Results
Validation of [11C]UCB-J binding in mice
To validate the specificity of [11C]UCB-J binding to
SV2A in the mouse, we performed a blocking study
with LEV. Baseline and blockade scans are shown in
Figure 1. The average SUV TACs during baseline
showed the rapid brain uptake of [11C]UCB-J, peaking
within the first 15min in the different investigated brain
regions, while the pretreatment with LEV at two differ-
ent doses (50 and 200mg/kg, i.p.) resulted in a manifest
decline of [11C]UCB-J binding (Figure 1(b)).
Accordingly, VT (IDIF) (Logan) values were significantly
reduced in all investigated brain regions following
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pretreatment with LEV in a dose-dependent manner
(e.g. in striatum: baseline¼ 5.17 0.34mL/cm3;
LEV50¼ 1.31 0.14mL/cm3, 74.6%, p< 0.0001;
LEV200¼ 0.82 0.04mL/cm3, 84.1%, p< 0.0001)
(Figure 1(c)). The effect of pretreatment with LEV on
[11C]UCB-J VT (IDIF) values for each individual region
and the estimated BPND are reported in Table 1.
To estimate the SV2A occupancy reached with the
pretreatment with LEV at the 2 different doses, we
applied the Lassen graphical analysis. A linear relation-
ship was observed for both doses (50 and 200mg/kg)
with fitted occupancy estimates of 79.2% and 97.3%,
respectively (Supplemental Figure 1), with the latter
indicating an approximate VND (IDIF) of 0.60mL/cm
3.
Kinetic analysis of [11C]UCB-J binding
in the mouse brain
Kinetic analysis was performed on the regional TACs
by applying different models, namely Logan plot,
1TCM, and 2TCM, in order to estimate VT (IDIF).
First, selection of the most appropriate model was per-
formed. The relative performance of each model was
evaluated in different brain regions. According to the
Figure 1. Validation of [11C]UCB-J binding in the mouse brain. (a) Effect of blockade with levetiracetam (LEV) on [11C]UCB-J uptake
in WT mice. Parametric microPET images are overlaid onto a MRI mouse brain template for anatomical localization. (b) SUV time-
activity curves in four brain regions during baseline and pretreatment with levetiracetam for a 90-min acquisition. (c) VT (IDIF) (Logan)
quantification during blockade resulted in a statistically significant reduced values in all investigated regions compared to baseline.
****p< 0.0001. Baseline: n¼ 10; LEV: n¼ 4 per dose. STR: striatum; THAL: thalamus; MC: motor cortex; HC: hippocampus;
VT (IDIF): total volume of distribution using IDIF.
Table 1. Effect of blockade of [11C]UCB-J binding using levetiracetam determined by Logan plot based on 90-min acquisition.
Baseline Pretreatment with levetiracetam Estimated BPND
VT (IDIF) (mL/cm
3) 50mg/kg 200mg/kg DVR-1
Region Mean SD Mean SD Diff (%) Mean SD Diff (%) Mean SD
Striatum 5.17 0.44 1.31 0.14 74.6§ 0.82 0.04 84.1§ 5.26 0.42
Thalamus 6.28 0.53 1.38 0.16 78.0§ 0.86 0.04 86.3§ 6.17 0.49
Motor cortex 5.46 0.48 1.16 0.10 78.7§ 0.74 0.05 86.4§ 6.22 0.51
Hippocampus 5.82 0.47 1.26 0.12 78.3§ 0.77 0.06 86.7§ 6.38 0.48
VT (IDIF): total volume of distribution using IDIF; BPND: non-displaceable binding potential; DVR: distribution volume ratio; Diff: difference.
§p< 0.0001.
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AIC values, where the model with the lowest value is
the preferred, the 1TCM appeared to be preferable
compared to 2TCM or Logan plot (e.g. in striatum:
1TCM¼ 40.9, 2TCM¼ 44.5, and Logan¼ 90.4)
(Supplemental table 2). The MSC values, where the
preferred model has the highest value, were in agree-
ment with the AIC values with 1TCM being slightly
better than 2TCM (e.g. in striatum: 1TCM¼ 2.6,
2TCM¼ 2.5) (Supplemental Table 3). Consistently,
the F-test indicated 1TCM as the preferred model
since the F-statistic was lower than the tabulated
F value (F¼ 3.3 for p¼ 0.05) in all investigated regions
(striatum¼ 0.6, thalamus¼ 0.7, motor cortex¼ 0.3,
hippocampus¼ 1.8, and cerebellum¼ 0.1).
The 1TCM microparameters and VT (IDIF) values as
well as the 2TCM and Logan plot VT (IDIF) values are
reported in Table 2. The microparameters for 2TCM
are not reported due to the low reliability (relative
standard errors were above 20%, especially for k3 and
k4). The estimated K1 values based on 1TCM were high,
ranging from 1.99 0.33mL/cm3/min in thalamus to
1.40mL/cm3/min in cerebellum, while the k2 were ran-
ging from 0.32 0.05 per min in cerebellum to
0.26 0.03 per min in motor cortex and hippocampus
(Table 2). Notably, the relative standard errors for
the K1 and k2 estimates based on 1TCM were low,
ranging from 1.6% to 6.4% for K1 and from 2.3%
to 8.8% for k2.
Comparison of VT (IDIF) values between 1TCM and
2TCM resulted in a nearly perfect correlation
(r¼ 0.999, p< 0.0001), with no deviation from the
identity line (slope¼ 1.002 and intercept¼þ0.004)
(Figure 2). Bland–Altman plot between the two
models confirmed the extremely high agreement
(bias¼0.26%) (Figure 2). On the contrary, the K1
estimates based on 2TCM were unstable and affected
by large relative standard errors (>20%) in one-third of
the samples. Thus, K1 estimates calculated with 2TCM
were overestimated for those samples compared to
1TCM, resulting in only a moderate correlation
between the 2 models (r¼ 0.565, p< 0.0001) with
deviation from the identity line (slope¼ 0.9429 and
intercept¼þ0.454) and a significant bias (17.82%)
according to the Bland-Altman plot as shown in
Figure 2.
VT (IDIF) values determined using the Logan plot
were consistently slightly underestimated when com-
pared to 1TCM or 2TCM, nonetheless showing
strong correlations (r¼ 0.973, p< 0.0001 and
r¼ 0.974, p< 0.0001, respectively), with negligible devi-
ation from the identity line (slope¼ 1.029 and inter-
cept¼þ0.397; slope¼ 1.031 and intercept¼þ0.399,
respectively) (Supplemental Figure 2). Bland–Altman
plots confirmed the consistent bias towards underesti-
mation of the VT (IDIF) values determined by Logan
plot compared to 1TCM and 2TCM (bias¼10.1%
and 10.28%, respectively) (Supplemental Figure 2).
Overall, 1TCM resulted in the most reliable model to
estimate both VT (IDIF) and K1 (IDIF) values in the
mouse brain. The average paramteric VT (IDIF) and K1
(IDIF) images of [
11C]UCB-J determined with 1TCM
and 90-min acquisition in the mouse brain are shown
in Figure 3(a), while the VT (IDIF) and K1 (IDIF) values
based on regional TACs are reported in Figure 3(b)
and (c).
To assess the time stability of the parameter estima-
tion, the effect of the scan duration on VT (IDIF) (1TCM
and Logan) and K1 (1TCM) values was investigated. As
shown in Figure 4, the VT (IDIF) and K1 (IDIF) values
based on 1TCM were stable, with a deviation of only
4.8 1.5% and 1.9 0.6%, respectively, when con-
sidering 60-min acquisition. VT (IDIF) values based on
Logan deviated 8.6 2.8% when shortening the acqui-
sition to 60min (Figure 4(c)). Importantly, comparison
Table 2. In vivo kinetic parameters of [11C]UCB-J determined using 1TCM, 2TCM, and Logan plot based on 90-min acquisition in
the mouse brain.
1TCM 2TCM Logan plot
K1(IDIF) (mL/cm
3/min) k2 (IDIF) (per min) VT (IDIF) (mL/cm
3) VT (IDIF) (mL/cm
3) VT (IDIF) (mL/cm
3)
Region Mean SD
COV
(%) Mean SD
COV
(%) Mean SD
COV
(%) Mean SD
COV
(%) Mean SD
COV
(%)
Striatum 1.52 0.21 13.67 0.27 0.029 10.85 5.63 0.43 7.67 5.66 0.44 7.91 5.17 0.34 6.69
Thalamus 1.99 0.33 16.91 0.28 0.037 13.12 6.96 0.55 7.94 6.98 0.54 7.79 6.28 0.43 6.85
Motor Cortex 1.59 0.28 17.78 0.26 0.03 14.13 6.00 0.47 7.91 6.01 0.48 7.94 5.46 0.38 6.97
Hippocampus 1.65 0.24 14.83 0.26 0.03 11.35 6.28 0.48 7.61 6.30 0.48 7.56 5.82 0.37 6.45
Cerebellum 1.40 0.27 19.62 0.32 0.05 17.35 4.41 0.35 8.03 4.42 0.36 8.07 3.82 0.27 7.05
Note: The microparameters for 2TCM are not reported due to the low reliability (relative standard errors were above 20%). 1TCM: one-tissue
compartmental model; 2TCM: two-tissue compartmental model; VT (IDIF): total volume of distribution using IDIF; COV: coefficient of variation.
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Figure 2. Comparison of the total volume of distribution (VT) and K1 values determined using 1TCM and 2TCM based on IDIF.
Correlation of the VT (IDIF) (a) and K1 (IDIF) (b) values calculated using 1TCM and 2TCM based on 90-min acquisition. The solid line
represents the linear regression, while the dashed line depicts the identity line. (c and d) Bland–Altman plot to compare 1TCM and
2TCM in estimation of VT (IDIF) and K1 (IDIF), respectively. Dashed line represents the bias between the two approaches, while the
dotted lines denote the 95% limits of agreement. n¼ 10. Each symbol represents a different region. 1TCM: one-tissue compartmental
model; 2TCM: two-tissue compartmental model; VT (IDIF): total volume of distribution using IDIF.
Figure 3. [11C]UCB-J PET imaging in the mouse brain. (a) Average microPET parametric images for VT (IDIF) and K1 (IDIF) of
[11C]UCB-J in healthy WT mice using 1TCM over 90-min acquisition. Parametric microPET images are overlaid onto a MRI mouse
brain template for anatomical localization. (b) Regional [11C]UCB-J VT (IDIF) values. (c) Regional [
11C]UCB-J K1 (IDIF) values. n¼ 10.
1TCM: one-tissue compartmental model; VT (IDIF) : total volume of distribution using IDIF; STR: striatum; TH: thalamus; MC: motor
cortex; HC: hippocampus; CB: cerebellum.
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of the VT (IDIF) and K1 (IDIF) values based on 90 and
60min resulted in excellent correlations with both
1TCM (VT (IDIF): r¼ 0.995, p< 0.0001, slope¼ 1.006
and intercept¼ –0.3472; K1: r¼ 0.998, p< 0.0001,
slope¼ 1.053 and intercept¼ –0.0432) and Logan plot
(VT (IDIF): r¼ 0.991, p< 0.0001, slope¼ 1.010 and
intercept¼ –0.5424) (Figure 4) indicating that a scan
acquisition of 60min is sufficient to obtain accurate
estimates.
Plasma metabolism of [11C]UCB-J
In vivo metabolism of [11C]UCB-J was relatively rapid.
The parent fraction in plasma of WT mice accounted
for 61.1 6.8%, 22.5 4.2%, 13.6 3.7%, and
9.5 3.4% of the total radioactivity at 5, 15, 30, and
45min p.i., respectively (Figure 5(a) and Supplemental
Table 4). Also, the percentage of unchanged [11C]UCB-
J in plasma of diseased mice (heterozygous for HD),
accounting for 62.8 3.6%, 21.6 5.6%, 15.5 4.3%,
and 6.9 3.9% of the total radioactivity at 5, 15, 30,
and 45min p.i., respectively, was comparable to the
values obtained in WT (Figure 5(a) and Supplemental
Table 4). Radiochromatograms of both WT and
diseased mice are shown in Supplemental Figure 3.
The values of parent fraction at the different times
p.i. in WT mice were corrected for the plasma-to-whole
blood ratio and fitted using a sigmoid curve in order to
generate a population-based curve of intact [11C]UCB-J
(Figure 5(b)), which was applied to the IDIF in order to
correct for metabolism as shown in Figure 5(c).
Comparison of the VT values based on Logan plot cal-
culated using the corrected and uncorrected IDIF in all
Waxholm atlas brain regions of five animals resulted in
a high correlation (r¼ 0.938; p< 0.0001, slope¼ 0.2117
and intercept¼þ0.53) (Figure 5(d)). Noteworthy, the
comparison of the VT values of each individual subject
resulted in even higher correlations (average r¼ 0.956,
p< 0.0001) (Figure 5(e)).
Discussion
Rodent models are vital to understanding pathophysi-
ology, identifying novel biomarkers, and testing candi-
date therapies to translate basic research findings into
clinical applications. In our present study, we aimed to
characterize [11C]UCB-J PET imaging in mice by vali-
dating the specificity of [11C]UCB-J binding to SV2A,
and to determine the optimal pharmacokinetic model
for noninvasive in vivo quantification. First, we vali-
dated the specificity of [11C]UCB-J by pretreating
mice with LEV and confirmed the dose-dependent
blockade of [11C]UCB-J binding site in the whole
brain as was expected given the ubiquitous distribution
of SV2A in the grey matter.3 We reached a LEV SV2A
occupancy of up to 97%, which corresponded to a
decrease of 86% in [11C]UCB-J VT (IDIF). This suggests
that only a small component of the total [11C]UCB-J
Figure 4. Time stability of the outcome parameters in different brain regions. VT (IDIF) and K1 (IDIF) calculated using 1TCM (a and b)
and VT (IDIF) based on Logan plot (c) normalized to the values obtained during 90-min acquisition. Correlations of the outcome
parameters VT (IDIF) and K1 (IDIF) calculated using 1TCM (d and e) and VT (IDIF) based on Logan plot (f) when shortening the acquisition
time from 90 to 60min. n¼ 10. 1TCM¼ one-tissue compartmental model, VT (IDIF)¼ total volume of distribution using IDIF.
8 Journal of Cerebral Blood Flow & Metabolism
brain uptake is related to VND, while the majority of
[11C]UCB-J is specifically binding to the target (VS).
This fairly low VND indicates [
11C]UCB-J PET imaging
might be applicable in target occupancy studies in mice
as was recently shown in humans.37
In addition to [11C]UCB-J, [11C]UCB-A and
[18F]UCB-H have been reported as radiotacers target-
ing SV2A.12,14 Both radiotracers have shown specific
binding to SV2A; however, [11C]UCB-A was limited
by its slow kinetics and metabolism in both rats and
pigs.12 On the other hand, [18F]UCB-H had good kin-
etics, but direct comparison with [11C]UCB-J in non-
human primates suggested the latter has higher specific
binding.11 Consistently, Warnock et al.38 reported a
decrease of approximately 44% in the whole-brain
[18F]UCB-H binding in rats pretreated with 100mg/kg
of LEV, while in the present study, with a 50mg/kg
dose in mice, we could observe a decrease of 78% of
the [11C]UCB-J binding to SV2A. Assuming a compar-
able VND across rodent species, this might be a further
indication of the higher specific binding of [11C]UCB-J
compared to [18F]UCB-H. However, comparative
studies in the same animals are recommended for a
conclusive assessment.
Previous studies reported the utility of white matter
structures (e.g. centrum semiovale) as reference region
for kinetic analysis in non-human primates and
humans11,15,37; however, the much smaller size of the
mouse brain did not allow the application of white
matter tissue as reference region even though
microPET scanners feature higher spatial resolution.
Alternatively, to perform noninvasive quantification,
it is possible to use an IDIF.39 Although this approach
is not suitable for absolute quantification, since it often
overestimates the blood activity, we previously vali-
dated it to be reliable for comparative studies.28
Kinetic analysis of the TACs indicated a near perfect
agreement between VT (IDIF) values estimated using
either 1TCM or 2TCM (r¼ 0.999). According to
model selection criteria (AIC, MSC, and F-test),
1TCM was the preferred model, as also suggested by
the more accurate K1 estimations in agreement with the
previously published human data.15 Indeed, in one-
third of the cases, K1 calculated using 2TCM was
unstable resulting in overestimation of the values,
hence the moderate correlation with K1 estimates deter-
mined with 1TCM (r¼ 0.565). This evidence suggests
2TCM could not adequately discriminate between K1
and k3 possibly due to [
11C]UCB-J kinetic profile.
Notably, the Logan plot seemed to be a valid alterna-
tive, despite showing a small but consistent underesti-
mation of the VT (IDIF) values. Nonetheless, the main
advantage of applying 1TCM is the ability to estimate
K1 values as an indication of the cerebral blood flow.
Figure 5. Population-based plasma metabolism of [11C]UCB-J in mice. (a) Population-based curve of intact [11C]UCB-J in plasma of
healthy wild-type (WT) and diseased (model of Huntington’s disease, HD) mice. n¼ 3 per genotype at each time point. (b) Sigmoid
fitting curve of the intact [11C]UCB-J in WT mice. (c) Comparison of representative image-derived input functions (IDIF) corrected
and uncorrected for the population-based sigmoid fitting of intact [11C]UCB-J. Scatter plots between VT (IDIF) (Logan) corrected and
uncorrected for the population-based sigmoid fitting of intact [11C]UCB-J based on a total of five WT mice (d) and correlations for
each individual WT mouse (e) in different brain regions. Individual animals presented different regression line equations.
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Importantly, reliable 1TCM-based parametric images
of both VT (IDIF) and K1 (IDIF) could be generated
for each subject, which was not the case when applying
the 2TCM.
We evaluated the time stability of the estimated VT
(IDIF) and K1 (IDIF) values to verify whether the 90-min
acquisition could be shortened. Overall, 60-min acqui-
sition resulted in <5% of deviation from the 90min
scan and nearly perfect correlations between the 2
measurements using 1TCM. Thus, [11C]UCB-J param-
eter estimation showed high stability, indicating the
possibility to reduce scan acquisition down to 60min
as recently shown in humans.15
Plasma analysis indicated a relatively rapid metabol-
ism of the tracer with generation of at least one radio-
metabolite that was more polar than [11C]UCB-J. This
result as well as the calculated parent fraction curve were
consistent with the literature.11,15 Nabulsi et al.11
reported the generation of at least two polar radiometa-
bolites in plasma of rats. Similarly, three polar radio-
metabolites were found in humans.15 In the present
study, only one radiometabolite peak could be deter-
mined. This could be related to the limited time reso-
lution of our setup (0.5min), which did not allow us to
discriminate between radiometabolites with similar
retention times. Concerning possible radiometabolites
in the brain, previous work reported only a minor
amount of radiometabolites (<1.5%) in the rat
brain11; however, such negligible amount could be
related to the blood volume fraction present in the
brain, which is estimated to approximately account for
3.6 to 4.1% of the total rat brain volume.27 Altogether,
the reported rat data and the clear blocking results from
the present study suggest that no brain-penetrant radio-
metabolites contribute to the brain PET signal.
Arterial blood sampling in mice is very challenging,
especially if applied to repeated scans (for instance the
blocking study), due to the limited amount of blood
that can be collected. Indeed, this often represents an
end of life procedure when using standard techniques
for metabolite analysis. A possible approach to circum-
vent this limitation and still be able to correct for
plasma radiometabolites is the use of a population-
based metabolite curve. An essential assumption in per-
forming a population-based correction is that the inter-
individual variation in the rate of metabolism is small
enough to avoid under- or over-corrections of the
plasma input curve and hence the VT. In addition, it
is conceivable that disease-specific animal models might
be characterized by different metabolism; in the present
study, we used an animal model of Huntington’s
Disease that did not show altered metabolic rate of
the radiotracer.
Even though we obtained strong correlations
between VT values calculated using the uncorrected
and population-based corrected IDIF, we observed
relevant changes in the slopes of the correlations
across animals. Given that the same correction was
applied to all subjects, this finding might suggest that
the assumption of low inter-individual variability was
not met, resulting in the introduction of inter-individual
variability between the two methods of analysis.
Overall, it appeared that correcting the IDIF for popu-
lation-based plasma metabolites did not represent an
improvement. Therefore, when performing compara-
tive studies in mice, the uncorrected IDIF curve can
be used, as long as there is no difference in rate of
metabolism between the investigated groups.
In conclusion, we showed that [11C]UCB-J select-
ively binds to SV2A in mice. The present study provides
the methodology based on 1TCM with IDIF for non-
invasive in vivo quantification of [11C]UCB-J PET ima-
ging in mice. Similar to the previously published work
on non-human primates and humans, [11C]UCB-J dis-
played optimal kinetics in mice, representing a promis-
ing tool for noninvasive quantification of synaptic
density in comparative rodent studies.
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